The Wellbutrin Naltrexone Combo: What You Need to Know

Combining bupropion (sold as Wellbutrin for depression, Zyban for smoking cessation) with naltrexone (an opioid-blocking drug) produces a weight-loss effect that neither drug achieves as strongly on its own. The fixed-dose combination, marketed as Contrave, is FDA-approved for chronic weight management in adults with obesity or overweight who have at least one weight-related health condition. Pooled results from four large trials show a placebo-subtracted weight loss of roughly 4.7% after one year, which places it in the moderate range among current obesity medications. But the story behind this combination goes beyond the headline numbers, touching on how the brain responds to food cues, why so many people stop taking it, and where it fits in a landscape increasingly dominated by GLP-1 drugs.

How the Two Drugs Work Together

Bupropion and naltrexone each affect appetite through different brain pathways, and combining them appears to produce a synergy that neither drug manages alone. Bupropion, a norepinephrine-dopamine reuptake inhibitor, stimulates neurons in the hypothalamus that help regulate appetite and energy expenditure. Those same neurons, however, release endorphins that loop back and dampen their own firing, which is thought to be one reason bupropion alone produces only modest weight loss. Naltrexone blocks opioid receptors, preventing that self-inhibiting feedback loop. The result is that the appetite-suppressing signal stays turned on longer.

Brain imaging research helps visualize this. In a study comparing the combination against placebo, the drug blunted activation in the hypothalamus in response to food cues while simultaneously boosting activity in brain regions tied to self-control and internal awareness, including the anterior cingulate cortex and the insula.¹ In plain terms, the combination quiets the part of the brain that screams “eat that” while turning up the volume on the part that says “wait, do I actually need that?” That dual action on both the drive to eat and the ability to resist eating is what makes the pairing more effective than either ingredient individually.

How Much Weight People Actually Lose

In the COR-II trial, one of the pivotal phase 3 studies, participants taking the naltrexone-bupropion combination lost about 6.4% of their body weight over 56 weeks, compared to 1.2% in the placebo group. Among those who completed the full year of treatment, the gap was even wider: 8.2% versus 1.4%.² About half of treated participants who stuck with the medication for a full year lost at least 5% of their starting weight, and a meaningful share hit 10% or more.

Across the four phase 3 trials collectively, the placebo-subtracted mean weight loss was roughly 4.7%, ranging from 3.2% to 5.2% depending on the trial population. The placebo-subtracted proportion of patients hitting the clinically significant 5% threshold ranged from 26% to 33%.³ Those numbers are meaningful for metabolic health, but they are substantially smaller than what newer GLP-1 receptor agonists deliver. For context, semaglutide (Wegovy) typically produces placebo-subtracted losses two to three times larger. This reality has reshaped who ends up on naltrexone-bupropion in practice: it tends to be prescribed when GLP-1 drugs are unavailable, unaffordable, or poorly tolerated.

Benefits for People With Type 2 Diabetes

One of the phase 3 trials focused specifically on people with type 2 diabetes, a population where even modest weight loss can meaningfully improve blood sugar control. In that study, participants taking the combination lost about 5% of their body weight versus 1.8% for placebo, and their hemoglobin A1c (a marker of average blood sugar over several months) dropped by 0.6 percentage points compared to 0.1 for placebo. Nearly 45% of patients on the drug brought their A1c below 7%, versus about 26% on placebo. The combination also improved triglycerides and HDL cholesterol.⁴ For someone with diabetes who cannot access a GLP-1 agonist, that combination of weight loss and blood sugar improvement represents a meaningful clinical benefit, even if the magnitude is more modest than what newer drugs achieve.

What It Does to Food Cravings

One of the most noticeable effects people report on this combination is reduced preoccupation with food, and there is research backing up that subjective experience. The brain-imaging study mentioned earlier found that the drug dampened hypothalamic activation while enhancing activity in self-control regions when participants were shown pictures of food.¹ Separately, a small study looking at naltrexone alone (without bupropion) found that its effect on cravings depended on a person’s baseline relationship with food. In women who scored high on “reward-based eating drive,” a measure of how strongly food acts as a reward, the 50-mg dose of naltrexone weakened the link between that drive and craving intensity. On placebo days, higher reward-based eating scores predicted stronger cravings; on naltrexone days, that connection essentially disappeared.⁵

This matters practically. If you have always felt that your appetite is less about physical hunger and more about the rewarding sensation of eating, this combination may address the specific neural wiring behind that experience. People whose overeating is more habitual or environment-driven may see less of a craving benefit, though the weight loss from other metabolic effects can still occur.

Side Effects and Why People Quit

Nausea is by far the most commonly reported side effect, and it is the main reason people stop taking the drug during the dose-escalation phase. The standard regimen starts at one tablet per day and gradually increases to two tablets twice daily over four weeks, specifically to ease people past the nausea window. Other frequently reported side effects include constipation, headache, dizziness, insomnia, dry mouth, and vomiting. Most of these tend to lessen after the first few weeks.⁶

The dropout rate is a significant concern. In a real-world Canadian chart review of 468 patients starting naltrexone-bupropion, only about 61% were still on the drug at four months and roughly 52% at six months.⁷ A larger U.S. analysis of over 26,000 patients newly prescribed various anti-obesity medications found that only 18.1% of people starting naltrexone-bupropion were still on it at six months, which was the lowest persistence rate among the four medications studied.⁸ The gap between Canadian and U.S. persistence figures likely reflects different healthcare systems and follow-up patterns, but the overall message is consistent: a large share of people who start this drug do not stay on it long enough to see the results the clinical trials demonstrated in completers.

This is one of the more frustrating features of naltrexone-bupropion. The people who make it to a year of treatment tend to see meaningful weight loss, but the road to that year is littered with dropouts, many of whom quit during the first month when side effects peak and weight loss has barely started. If you are considering this medication, understanding that the nausea is front-loaded and usually temporary can help set realistic expectations.

Who Should Not Take It

The contraindications for this combination are driven primarily by the bupropion component. Bupropion lowers the seizure threshold, so the combination is contraindicated in anyone with a current or prior seizure disorder, a known brain tumor, or anyone going through acute alcohol or benzodiazepine withdrawal, both of which already increase seizure risk. Caution is also warranted if you take other medications that lower the seizure threshold, or if you have a history of head trauma.⁹

The naltrexone component creates a separate and potentially dangerous problem for anyone taking opioids. Because naltrexone blocks opioid receptors, taking it while physically dependent on opioids, including prescription painkillers and medications like methadone or buprenorphine used for opioid use disorder, can trigger severe withdrawal. Life-threatening reactions have been reported. Anyone stopping opioid therapy must wait at least seven to ten days before starting the combination. Conversely, if opioid pain treatment becomes necessary later, the naltrexone-bupropion must be stopped first.¹⁰ This also means the drug can interfere with opioid-based anesthesia and emergency pain management, so anyone on naltrexone-bupropion should make sure this information is in their medical records and inform any new healthcare provider.

The Cardiovascular Safety Question

The FDA’s path to approving naltrexone-bupropion was unusually rocky, largely because of worries about the heart. During the phase 3 trials, the combination caused small increases in blood pressure and heart rate, enough to make the FDA initially defer approval and demand a dedicated cardiovascular outcomes trial before clearing the drug for market.¹¹

That trial, called the Light Study, enrolled overweight and obese patients with cardiovascular risk factors and compared major adverse cardiovascular events between the combination and placebo. At an interim analysis after 25% of expected events had occurred, the results were leaked publicly before the study could finish, which compromised its scientific integrity and led to early termination. The available data showed that, at 16 weeks, the mean blood pressure increase with the drug versus placebo averaged less than half a millimeter of mercury, and heart rate increased by less than one beat per minute.¹² Those are tiny changes in absolute terms, but the trial’s premature end meant the question of long-term cardiovascular safety was never definitively answered. The drug remains on the market, and no excess of heart attacks or strokes has emerged in post-marketing surveillance, but the incomplete trial is a gap in the evidence that clinicians are aware of.

Use in Binge-Eating Disorder

Given that naltrexone-bupropion affects reward pathways and food-related brain activity, researchers have tested it in binge-eating disorder, where episodes of uncontrolled eating are the core problem rather than overall calorie intake. The results have been mixed in a way that tells an interesting story.

A pilot randomized trial found that while participants on the combination saw improvements in binge-eating frequency, depression, and weight during treatment, those improvements did not significantly differ from placebo on most measures. The one exception was that a significantly greater proportion of people on the drug achieved at least 3% weight loss compared to placebo.¹³ A larger trial reached a similar conclusion: the combination did not demonstrate effectiveness for reducing binge eating specifically, but it did produce significant weight loss in patients with the disorder.¹⁴

However, a separate trial that combined the medication with behavioral weight loss therapy found something more promising. When naltrexone-bupropion was paired with structured behavioral therapy, binge-eating remission rates reached 57%, compared to 37% with therapy alone, 31% with medication alone, and 18% with placebo. Both the medication and the behavioral therapy independently improved binge-eating outcomes, though combining them did not produce a synergy beyond what adding their individual effects would predict.¹⁵ The takeaway for people with binge-eating disorder is that the drug alone probably will not fix the binge episodes, but it can help with weight and may enhance the benefits of therapy.

Early Research on Alcohol Use

Naltrexone alone is already FDA-approved for alcohol use disorder, and bupropion is sometimes prescribed off-label to help with cravings. This has naturally raised the question of whether their combination might be particularly effective for problem drinking. The human evidence is still thin, but animal research has been suggestive. In a study using alcohol-preferring rats, low doses of naltrexone and bupropion given individually did not significantly reduce alcohol intake, but combining them did. Interestingly, the reduction in drinking was not accompanied by weight loss in these animals, contrasting with the drug’s intended use in humans.¹⁶

This is preclinical work, meaning you cannot directly apply the results to people. But the underlying logic tracks with what we know about each drug’s mechanism: naltrexone blocks the opioid-mediated pleasure of drinking, and bupropion may reduce the dopamine-driven craving. Whether those effects combine meaningfully in humans at the doses used in Contrave remains an open question. It is worth mentioning because some clinicians already consider the combination in patients who have both obesity and problematic alcohol use, even though this specific indication has not been tested in a formal human trial of the fixed-dose product.

Real-World Persistence and What It Means for Results

The disconnect between clinical trial results and real-world outcomes deserves emphasis, because it shapes what you should realistically expect. In clinical trials, participants are actively monitored, encouraged, and followed up with regularly. Even so, a significant number dropped out. In the less structured environment of routine clinical care, the attrition is substantially worse. The U.S. persistence data, showing only about 18% still taking the drug at six months, means that more than four out of five people prescribed naltrexone-bupropion abandon it within half a year.⁸

The Canadian chart review paints a somewhat less bleak picture with about 52% still on treatment at six months, possibly reflecting differences in patient support or healthcare access.⁷ Either way, the practical implication is clear: the clinical trial numbers showing 6-8% weight loss at one year describe a best-case scenario for people who stick with the medication. If you fill the prescription and stop after six weeks because of nausea or because the scale has not moved much yet, your experience will not resemble those trial results. Knowing this upfront, and having a plan to push through the early weeks with your prescriber’s guidance, may be the single most important factor in whether the drug works for you.

When Bupropion Is Already in the Picture

A common question arises among people already taking bupropion (Wellbutrin) for depression or anxiety: can they simply add naltrexone to get the weight-loss effect? In theory, the same two chemicals are at work. In practice, the doses and formulations differ. Contrave uses sustained-release versions of both drugs at specific doses (each tablet contains 8 mg naltrexone and 90 mg bupropion), titrated up to a target of 32 mg naltrexone and 360 mg bupropion daily. Someone already on Wellbutrin XL 300 mg, for example, would be close to the bupropion dose but would need the naltrexone component added separately, and the total bupropion dose from combining both products could exceed safe limits.

Some prescribers do add generic naltrexone to existing bupropion therapy as an off-label strategy, adjusting doses accordingly. This approach can be significantly cheaper than the brand-name combination product. But it requires careful dose management, particularly to keep total bupropion exposure within the range where seizure risk remains low. This is not something to freelance, as the interaction between the two drugs is the entire point, and getting the balance wrong has real safety consequences. If you are already on bupropion and interested in the combination, the conversation with your prescriber should focus on total daily doses, seizure risk factors, and whether the sustained-release formulation matters for your situation.